Yttrium-90 (y90) Microsphere Injection Solution was approved by the NMPA in 2022. Currently, there is a lack of summary of real-world data in China. Therefore, this retrospective real-world study is intented to explore the characteristics and efficacy of HCC patients treated with y90 in China, aiming to provide reference for guiding and optimizing clinical practices and subsequent confirmatory clinical studies for the treatment of HCC patients in China.
Study Type
OBSERVATIONAL
Enrollment
100
selective internal radiation therapy
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Jinan University
Jinan, Guangdong, China
Xi'An International Medical Center Hospital
Xi’an, Guangxi, China
No.1 Affiliated Hospital of Xian Jiaotong University
Xi’an, Shanxi, China
best hepatic ORR measured by mRECIST criteria
Time frame: 6 months following y90 therapy
ORR measured by mRECIST criteria
Time frame: 6 months following y90 therapy
OS
Time frame: From date of first Y90 therapy until the date of death from any cause, assessed up to 24 months
TTP
time to progression
Time frame: From date of first Y90 therapy until the date of first documented progression, assessed up to 24 months
PFS
Time frame: From date of first Y90 therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame: 6 months following y90 therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Beijing Tsinghua Changgung Hospital
Beijing, China
The Third Affiliated Hospital of Naval Medical University
Shanghai, China